

CITATION REPORT

List of articles citing

The clinical pharmacology of lisinopril

DOI: 10.1097/00005344-198700003-00008

Journal of Cardiovascular Pharmacology, 1987, 9 Suppl 3, S27-34.

Source: <https://exaly.com/paper-pdf/18767138/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
60	Lisinopril versus lisinopril plus hydrochlorothiazide in essential hypertension. <i>American Journal of Cardiology</i> , 1988 , 61, 803-6	3	9
59	Angiotensin converting enzyme inhibitors. II. Clinical use. <i>American Heart Journal</i> , 1988 , 116, 1591-605	4.9	41
58	Clinical experience and rationale for angiotensin-converting enzyme inhibition with lisinopril as the initial treatment for hypertension in older patients. <i>American Journal of Medicine</i> , 1988 , 85, 19-24	2.4	6
57	Efficacy and safety of lisinopril in older patients with essential hypertension. <i>American Journal of Medicine</i> , 1988 , 85, 35-7	2.4	10
56	Antihypertensive and renal effects of lisinopril in older patients with hypertension. <i>American Journal of Medicine</i> , 1988 , 85, 38-43	2.4	8
55	Lisinopril: dose-peak effect relationship in essential hypertension. <i>British Journal of Clinical Pharmacology</i> , 1988 , 25, 533-8	3.8	25
54	ACE INHIBITORS—THE TRICKLE BECOMES A FLOOD. <i>Lancet, The</i> , 1988 , 332, 885-886	4.0	1
53	SURGICAL INSURRECTION. <i>Lancet, The</i> , 1988 , 332, 884-885	4.0	
52	Converting-enzyme inhibitors in the treatment of hypertension. <i>New England Journal of Medicine</i> , 1988 , 319, 1517-25	59.2	273
51	Lisinopril: a new angiotensin-converting enzyme inhibitor. <i>Drug Intelligence & Clinical Pharmacy</i> , 1988 , 22, 365-72		25
50	Lisinopril: a new angiotensin-converting enzyme inhibitor. <i>Pharmacotherapy</i> , 1989 , 9, 120-8; discussion 128-30	5.8	5
49	Comparison of lisinopril versus placebo for congestive heart failure. <i>American Journal of Cardiology</i> , 1989 , 63, 12D-16D	3	20
48	Recent advances in pharmaceutical chemistry--angiotensin-converting enzyme inhibitors. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1989 , 14, 341-54	2.2	2
47	Initial drug therapy for hypertensive patients with hyperlipidemia. <i>American Heart Journal</i> , 1989 , 118, 1012-21	4.9	19
46	Lisinopril dose-response relationship in essential hypertension. <i>British Journal of Clinical Pharmacology</i> , 1989 , 28, 415-20	3.8	20
45	Angiotensin-converting enzyme inhibitors in heart failure. <i>Medical Clinics of North America</i> , 1989 , 73, 315-38	7	11
44	Antihypertensive drugs. <i>Side Effects of Drugs Annual</i> , 1989 , 173-182	0.2	2

43	Benazepril. <i>Cardiovascular Drug Reviews</i> , 1990 , 8, 89-104		26
42	Pharmacology of angiotensin-converting enzyme inhibitors as a guide to their use in congestive heart failure. <i>American Journal of Cardiology</i> , 1990 , 66, 7D-11D; discussion 11D-13D	3	10
41	Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quinapril and its active metabolite (quinaprilat). <i>Biopharmaceutics and Drug Disposition</i> , 1990 , 11, 191-6	1.7	9
40	Angiotensin-converting enzyme inhibitors and renal function. <i>DICP: the Annals of Pharmacotherapy</i> , 1990 , 24, 496-505		21
39	Once-daily lisinopril compared with twice-daily captopril in the treatment of mild to moderate hypertension: assessment of office and ambulatory blood pressures. <i>Journal of Clinical Pharmacology</i> , 1990 , 30, 1074-80	2.9	21
38	Angiotensin-converting enzyme inhibitors: a comparative review. <i>DICP: the Annals of Pharmacotherapy</i> , 1990 , 24, 506-25		26
37	Anesthetic implications of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. <i>Anesthesia and Analgesia</i> , 1991 , 72, 667-83	3.9	46
36	ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. <i>Teratology</i> , 1991 , 44, 485-95		153
35	Comparison between enalapril and lisinopril in mild-moderate hypertension: a comprehensive model for evaluation of drug efficacy. <i>Blood Pressure</i> , 1992 , 1, 102-7	1.7	12
34	A comparison of the effect of lisinopril and hydrochlorothiazide on electrolyte balance in essential hypertension. <i>European Journal of Clinical Pharmacology</i> , 1992 , 42, 487-90	2.8	3
33	Comparative pharmacokinetic and clinical profiles of angiotensin-converting enzyme inhibitors and calcium antagonists in systemic hypertension. <i>American Journal of Cardiology</i> , 1992 , 69, 17C-25C	3	7
32	The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol. <i>European Journal of Clinical Pharmacology</i> , 1993 , 45, 255-60	2.8	5
31	Efficacy of once-daily lisinopril monotherapy in systemic hypertension. <i>Clinical Cardiology</i> , 1993 , 16, 129-33	3.3	3
30	Lisinopril versus hydrochlorothiazide in mild-to-moderate systolic/diastolic or isolated systolic hypertension in the elderly. <i>Current Therapeutic Research</i> , 1993 , 54, 779-787	2.4	1
29	Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. <i>Clinical Pharmacokinetics</i> , 1993 , 24, 230-54	6.2	54
28	Physiological changes due to age. Implications for drug therapy of congestive heart failure. <i>Drugs and Aging</i> , 1993 , 3, 320-34	4.7	10
27	Optimising ACE inhibitor therapy of congestive heart failure. Insights from pharmacodynamic studies. <i>Clinical Pharmacokinetics</i> , 1993 , 24, 59-70	6.2	10
26	ACE inhibition versus calcium antagonism in the treatment of mild to moderate hypertension: a multicentre study. Ireland-Netherlands Lisinopril-Nifedipine Study Group. <i>Postgraduate Medical Journal</i> , 1993 , 69, 450-5	2	3

25	Effects of exercise and therapy on ventricular emptying and filling in mildly hypertensive patients. <i>American Journal of Hypertension</i> , 1994 , 7, 695-702	2.3	9
24	Teratogen update: angiotensin-converting enzyme inhibitors. <i>Teratology</i> , 1994 , 50, 399-409		162
23	A Comparative Study of the Efficacy and Safety of Quinapril and Lisinopril in Patients with Mild to Moderate Hypertension. <i>Drug Investigation</i> , 1994 , 7, 13-17		11
22	Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. <i>European Heart Journal</i> , 1995 , 16, 1120-5	9.5	14
21	Trough-to-peak versus surface ratio in the assessment of antihypertensive agents. APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension. <i>Blood Pressure</i> , 1995 , 4, 350-7	7.7	11
20	ACE inhibitors. Drug interactions of clinical significance. <i>Drug Safety</i> , 1995 , 12, 334-47	5.1	25
19	Clinical pharmacokinetics of vasodilators. Part I. <i>Clinical Pharmacokinetics</i> , 1998 , 34, 457-82	6.2	52
18	Angiotensin-converting enzyme inhibitors. <i>Advances in Protein Chemistry</i> , 2001 , 56, 13-75		44
17	Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 961-6	4.3	41
16	Prediction of drug bioavailability based on molecular structure. <i>Analytica Chimica Acta</i> , 2003 , 485, 89-102	6.6	42
15	Bioavailability prediction based on molecular structure for a diverse series of drugs. <i>Pharmaceutical Research</i> , 2004 , 21, 68-82	4.5	51
14	Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers. <i>Biopharmaceutics and Drug Disposition</i> , 2005 , 26, 335-9	1.7	7
13	A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. <i>Pediatric Nephrology</i> , 2007 , 22, 695-701	3.2	25
12	Design of a Dissolving Microneedle Platform for Transdermal Delivery of a Fixed-Dose Combination of Cardiovascular Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2015 , 104, 3490-500	3.9	59
11	Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension. <i>Drug Delivery</i> , 2016 , 23, 579-90	7	20
10	Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 383-401	6.2	15
9	Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model. <i>BMC Pharmacology & Toxicology</i> , 2020 , 21, 56	2.6	4
8	Time-Dependent Effects of Individual and Combined Treatments With Nebivolol, Lisinopril, and Valsartan on Blood Pressure and Vascular Reactivity to Angiotensin II and Norepinephrine. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 490-499	2.6	

7	Angiotensin-Converting Enzyme Inhibitor Fetopathy. <i>Handbook of Experimental Pharmacology</i> , 1997 , 265-294	3.2	3
6	Case report: severe symptomatic hyponatremia associated with lisinopril therapy. <i>American Journal of the Medical Sciences</i> , 1992 , 303, 177-9	2.2	24
5	The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. The APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension Trial. <i>Hypertension</i> , 1995 , 26, 942-9	8.5	21
4	L. 1991 , 326-346		
3	Severe angioedema and respiratory distress associated with lisinopril use. <i>Western Journal of Medicine</i> , 1993 , 158, 412-7		4
2	Development and Validation of an HPLC-FLD Method for the Determination of NDMA and NDEA Nitrosamines in Lisinopril Using Pre-Column Denitrosation and Derivatization Procedure. 2022 , 9, 347		○
1	Top 10 Prescribed Drugs: What Do Dental Clinicians Need To Know. 2021 , 49, 261-268		○